ERLOTINIB TEVA 25 MG

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

ERLOTINIB AS HYDROCHLORIDE

Available from:

TEVA ISRAEL LTD

ATC code:

L01XE03

Pharmaceutical form:

FILM COATED TABLETS

Composition:

ERLOTINIB AS HYDROCHLORIDE 25 MG

Administration route:

PER OS

Prescription type:

Required

Manufactured by:

TEVA ISRAEL LTD, ISRAEL

Therapeutic area:

ERLOTINIB

Therapeutic indications:

Non-Small Cell Lung Cancer (NSCLC): Erlotinib Teva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations. Erlotinib Teva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy. Erlotinib Teva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.Pancreatic cancer: Erlotinib Teva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Authorization date:

2021-08-30